CN111281939A - Composition for nourishing stomach, protecting liver and dispelling effects of alcohol and preparation method thereof - Google Patents
Composition for nourishing stomach, protecting liver and dispelling effects of alcohol and preparation method thereof Download PDFInfo
- Publication number
- CN111281939A CN111281939A CN202010237660.7A CN202010237660A CN111281939A CN 111281939 A CN111281939 A CN 111281939A CN 202010237660 A CN202010237660 A CN 202010237660A CN 111281939 A CN111281939 A CN 111281939A
- Authority
- CN
- China
- Prior art keywords
- stirring
- composition
- liver
- powder
- stomach
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002784 stomach Anatomy 0.000 title claims abstract description 37
- 210000004185 liver Anatomy 0.000 title claims abstract description 34
- 230000002633 protecting effect Effects 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract description 53
- 230000000694 effects Effects 0.000 title abstract description 37
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 19
- 229940013618 stevioside Drugs 0.000 claims abstract description 19
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000019202 steviosides Nutrition 0.000 claims abstract description 19
- 229920002472 Starch Polymers 0.000 claims abstract description 16
- 235000019698 starch Nutrition 0.000 claims abstract description 16
- 239000008107 starch Substances 0.000 claims abstract description 16
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 12
- 241001313857 Bletilla striata Species 0.000 claims abstract description 11
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 9
- 235000010804 Maranta arundinacea Nutrition 0.000 claims abstract description 9
- 235000012419 Thalia geniculata Nutrition 0.000 claims abstract description 9
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 9
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 7
- 244000145580 Thalia geniculata Species 0.000 claims abstract 5
- 239000000843 powder Substances 0.000 claims description 66
- 238000003756 stirring Methods 0.000 claims description 57
- 239000000463 material Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 21
- 238000007873 sieving Methods 0.000 claims description 21
- 206010019133 Hangover Diseases 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 229910000831 Steel Inorganic materials 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 238000007639 printing Methods 0.000 claims description 5
- 230000007480 spreading Effects 0.000 claims description 5
- 238000003892 spreading Methods 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- 239000010959 steel Substances 0.000 claims description 5
- 241001313855 Bletilla Species 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 238000007781 pre-processing Methods 0.000 claims description 2
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 18
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 230000002829 reductive effect Effects 0.000 abstract description 7
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 abstract description 6
- 229960000458 allantoin Drugs 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 150000004676 glycans Chemical class 0.000 abstract description 5
- 229920001282 polysaccharide Polymers 0.000 abstract description 5
- 239000005017 polysaccharide Substances 0.000 abstract description 5
- 208000025865 Ulcer Diseases 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 231100000397 ulcer Toxicity 0.000 abstract description 4
- 206010017788 Gastric haemorrhage Diseases 0.000 abstract description 3
- 208000032843 Hemorrhage Diseases 0.000 abstract description 3
- 230000000740 bleeding effect Effects 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 abstract description 2
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 2
- 201000005917 gastric ulcer Diseases 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 description 38
- 241000700159 Rattus Species 0.000 description 33
- 235000019441 ethanol Nutrition 0.000 description 31
- 238000005303 weighing Methods 0.000 description 21
- 230000035622 drinking Effects 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 208000010706 fatty liver disease Diseases 0.000 description 14
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 13
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 13
- 244000046146 Pueraria lobata Species 0.000 description 13
- 235000010575 Pueraria lobata Nutrition 0.000 description 13
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 13
- 230000006872 improvement Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 235000002723 Dioscorea alata Nutrition 0.000 description 12
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 12
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 12
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 12
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 235000004879 dioscorea Nutrition 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 10
- 108010082126 Alanine transaminase Proteins 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 10
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 9
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 244000151018 Maranta arundinacea Species 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000021147 sweet food Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 241001104043 Syringa Species 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 230000006578 abscission Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012490 blank solution Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- YBZZAVZIVCBPDJ-UHFFFAOYSA-N schizandrin B Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)(O)CC2=CC2=C1OCO2 YBZZAVZIVCBPDJ-UHFFFAOYSA-N 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 241001038563 Pseudostellaria Species 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 238000009447 edible packaging Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a composition for nourishing stomach, protecting liver and relieving alcoholism and a preparation method thereof, wherein the composition comprises the following raw materials: the weight ratio of the schisandra fruit, the arrowroot, the bletilla striata, the yam, the starch and the stevioside is (1-3): 2-5): 0.9-1.2): 1.5-2.0): 0.002-0.005. The polysaccharide and the allantoin contained in the formula have the effects of resisting bacteria, stopping bleeding and promoting ulcer healing, and after the edible allantoin-containing gastric mucosa gel is eaten, the allantoin-containing gastric mucosa gel absorbs water and expands to form a biomembrane which has good biocompatibility and strong adhesiveness and covers the gastric mucosa, so that the absorption of alcohol is reduced, the stimulation of the alcohol to the gastric mucosa is inhibited, the gastric bleeding is inhibited, and the healing of the gastric ulcer is promoted.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine and food, in particular to a composition for nourishing stomach, protecting liver and alleviating hangover and a preparation method thereof.
Background
China is a ceremony nation, food culture is rich, ancient people have the theory of no wine and no seat, people gather wine and help in the middle of the year, but alcohol in wine has irritation and lipid solubility, after drinking, the alcohol is firstly absorbed through stomach and intestine and then metabolized through liver, the normal drinking and the drunkenness easily cause stomach and liver damage, excessive drinking or drunkenness causes vomiting and acid regurgitation, serious patients have acute gastric mucosa injury to cause upper gastrointestinal hemorrhage, reflux esophagitis and the like, the normal drinking and the drunkenness cause heavy liver load, liver cells are phagocytized by alcohol, damaged and enzyme inactivated to influence normal metabolism, alcoholism causes alcoholic intoxication, forms alcoholic fatty liver, cirrhosis and liver cancer, drinking can aggravate hypertension and induce stroke, the drunk wine can cause a great deal of harm to human bodies, health problems caused by the normal drinking and the normal drinking cause wide attention to society, adverse reactions, the drunkenness relieving and drunkenness relieving effect of functional foods with the drunkenness relieving effects, liver and alcohol relieving effects cause heavy fatty liver cirrhosis, liver cancer, drinking and stroke, the market only has the traditional Chinese medicine formula with the advantages of no toxic effect of relieving drunkenness, no harm to cause heavy alcohol relieving drunkenness, only has the traditional Chinese medicine consumption, only has the traditional Chinese medicine formula with the traditional Chinese medicine formula of high alcohol relieving drunkenness relieving effect, only has the traditional Chinese medicine formula, the traditional medicine formula of high price, the traditional medicine formula of relieving drunkenness of relieving drunkenness relieving.
Disclosure of Invention
Aiming at the problems, the invention provides a product which is prepared from pure traditional Chinese medicines in Wudangshan and Shennong's way, namely a composition for nourishing the stomach, protecting the liver and alleviating hangover, which is taken daily or before and after drinking to reduce the damage of alcohol to the stomach and the liver.
In order to achieve the purpose, the invention provides the following scheme:
the invention provides a composition for nourishing stomach, protecting liver and relieving alcoholism, which comprises the following raw materials: the weight ratio of the schisandra fruit, the arrowroot, the bletilla striata, the yam, the starch and the stevioside is (1-3): 2-5): 0.9-1.2): 1.5-2.0): 0.002-0.005.
As a further improvement of the invention, the weight ratio of the schisandra chinensis, the arrowroot, the bletilla striata, the yam, the starch and the stevioside is 2:4:1.1:1.1:1.8:0.004 in sequence.
The invention provides a preparation method of a composition for nourishing stomach, protecting liver and alleviating hangover, which comprises the following steps:
(1) preprocessing schisandra chinensis, arrowroot, rhizoma bletillae, yam and starch in the raw materials to obtain corresponding powder;
(2) sieving stevioside, mixing stevioside and radix Puerariae powder, placing in a stirrer, and stirring;
(3) adding rhizoma bletilla powder into the stirrer for 2 times, and stirring;
(4) adding the yam powder into a stirrer for 2 times, and stirring;
(5) adding starch into a stirrer for 2 times, and stirring;
(6) adding fructus Schisandrae chinensis powder into a stirrer for 2 times, and stirring;
(7) uniformly spreading the material obtained in the step (6) on a stainless steel flat plate, sterilizing and cooling to room temperature;
(8) subpackaging, printing code and labeling, and packaging.
As a further improvement of the invention, the processes from step (1) to step (8) are completed in a 10 ten thousand grade purification environment.
As a further improvement of the invention, the pretreatment in the step (1) is to bake in an oven firstly, then sieve and collect the powder. The kudzu powder is preferably Shennong kudzu powder, the Shennong kudzu powder is baked in an oven at 50 ℃ (± 5 ℃) for 60-90 min, and is sieved by a 60-mesh sieve, and white fine powder below the sieve is collected for later use. Preferably, the starch is baked in an oven at 50 ℃ (± 5 ℃) for 50-60 min, and is sieved by a 60-mesh sieve, and white fine powder below the sieve is collected for later use. The bletilla striata is preferably selected from the rhizome of common bletilla pseudostellaria, baked in an oven at 60 ℃ (± 5 ℃) for 90-120 min, crushed, sieved by a 60-mesh sieve, and collected under-sieve yellow fine powder for later use. The yam is preferably Wudang yam, is baked for 90-120 min at 60 ℃ (+ -5 ℃), is ground and is sieved by a 60-mesh sieve, and white fine powder below the sieve is collected for later use. The fructus schisandrae chinensis is preferably selected from Wudanghongling fructus schisandrae chinensis, baked in an oven at 50 ℃ (± 5 ℃) for 90-120 min, crushed, sieved by a 60-mesh sieve, and brownish black fine powder below the sieve is collected for later use.
As a further improvement of the invention, in the step (2), the stevioside is sieved by a steel sieve with the caliber of 12cm and the mesh of 60, and then is mixed with the arrowroot, the rotating speed of a stirrer is 50-70r/min, and the stevioside is stirred at a constant speed for 10-20 min. Preferably, the rotation speed is 60r/min, and the stirring is carried out for 15 min.
As a further improvement of the invention, the bletilla striata powder in the step (3) is added at intervals of 5-8min for 2 times, the rotating speed of the stirrer is 50-70r/min, and the uniform stirring is carried out for 10-20 min. Preferably, the rotation speed is 60r/min, and the stirring is carried out for 15 min.
As a further improvement of the invention, the yam in the step (4) and the starch in the step (5) are respectively added at intervals of 5-8min for 2 times, the rotating speed of the stirrer is 50-70r/min, and the uniform stirring is carried out for 10-20 min. Preferably, the rotation speed is 60r/min, and the stirring is carried out for 15 min.
As a further improvement of the invention, the schisandra chinensis powder in the step (6) is added at intervals of 5-8min for 2 times, the rotating speed of the stirrer is 50-70r/min, and the stirring is carried out at a constant speed for 25-35 min. Preferably, the rotation speed is 60r/min, and the stirring is carried out for 30 min.
As a further improvement of the invention, the dispersion thickness in the step (7) is 1-2cm, and the sterilization is carried out for 20-30min at 70-90 ℃.
The formula of the invention has the following characteristics:
(1) the Wudanghongling plum, the Wudangshan yam, the Shennong lian cao and the Shennong kudzu vine used in the formula are cultivated and planted under the special climatic conditions of the Wudangshan mountain and the Shennong shelf area, have bright regional characteristics and rich active ingredient structures, the auxiliary material starch is processed from corn, the flavoring stevioside is an extract of stevia rebaudiana, and the functional food researched and developed on the basis of the raw materials belongs to a pure natural plant formula, does not contain any chemical additive, and is non-toxic, free of side effect, safe and edible as a medicine.
(2) The formula of the invention contains deoxyschizandrin and schisandrin B, which can reduce the release of transaminase, promote protein synthesis, stabilize liver cell membrane, improve liver cell structure, improve human immunity, inhibit the formation of alcoholic fatty liver and liver cirrhosis, enhance spirit and relieve fatigue after being absorbed by human body.
(3) The formula of the invention contains puerarin, flavone, amino acid, multiple vitamins and trace elements, and the invention has the functions of relieving alcoholism and promoting urination, detoxifying, improving microcirculation and softening cardiovascular and cerebrovascular after eating, and is beneficial to improving hypertension, reducing blood sugar, inhibiting cerebral infarction, preventing cancer, relieving thirst, dryness-heat and the like caused by drinking.
(4) The polysaccharide and the allantoin contained in the formula have the effects of resisting bacteria, stopping bleeding and promoting ulcer healing, and after the edible allantoin-containing gastric mucosa gel is eaten, the allantoin-containing gastric mucosa gel absorbs water and expands to form a biomembrane which has good biocompatibility and strong adhesiveness and covers the gastric mucosa, so that the absorption of alcohol is reduced, the stimulation of the alcohol to the gastric mucosa is inhibited, the gastric bleeding is inhibited, and the healing of the gastric ulcer is promoted.
(5) The food is separately packaged in single dose of powder (bags), capsules and pop cans, is convenient to eat, and is delicious and tasty.
The invention discloses the following technical effects:
according to the invention, according to the physiological characteristics of human bodies, the absorption and metabolism principles after drinking and the pharmacological action of active substances contained in traditional Chinese medicines, raw materials are screened, accurate components are formulated, scientific preparation process, edible packaging specification and quality control standard and method are formulated, animal experiments and clinical researches are developed, and functional medicinal and edible health-care food with stable and controllable quality, exact effect, no toxicity, safety, comfortable mouthfeel, convenient use and economy is formed, thereby meeting the requirements of daily health care and life quality improvement of people.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without inventive exercise.
FIG. 1 is a photograph of the raw material powder to be mixed in example 1;
FIG. 2 is a diagram of a semi-finished product to be packaged in accordance with example 1;
FIG. 3 is a high performance liquid chromatogram of a reference sample, a test sample and a blank sample;
FIG. 4 is a diagram of the morphology of the gastric mucosa of rats in each group;
FIG. 5 is a histopathological morphology of rat stomach in each group.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The specification and examples are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
Example 1
(1) Pretreatment of raw materials: weighing Shennong kudzu vine powder (kudzu powder) and baking in an oven at 50 +/-5 ℃ for 60min, sieving with a 60-mesh sieve, and collecting 400g of undersize white fine powder for later use; weighing corn starch, baking for 50min at 50 +/-5 ℃ in an oven, sieving with a 60-mesh sieve, and collecting 180g of undersize white fine powder for later use; weighing decoction pieces of herba Centellae (rhizoma Bletillae), baking in an oven at 60 + -5 deg.C for 90min, pulverizing, sieving with 60 mesh sieve, and collecting yellow fine powder 110g under the sieve for use; weighing rhizoma Dioscoreae, baking in oven at 60 + -5 deg.C for 90min, pulverizing, sieving with 60 mesh sieve, and collecting white fine powder 110 g; weighing the Wudanghongling Chinese magnoliavine fruit, baking for 90min at 50 +/-5 ℃ in an oven, crushing, sieving with a 60-mesh sieve, and collecting 200g of brownish black fine powder below the sieve for later use;
(2) mixing: sieving stevioside with a steel sieve with a diameter of 12cm and a 60-mesh sieve, mixing 0.4g stevioside and shennong kudzu vine powder, placing the mixed material in a stirring tank of a stirring machine, rotating the stirring machine to 60r/min at a high speed, stirring at a constant speed for 15min, adding bletilla striata powder into the stirring machine at intervals of 5min for 2 times, stirring at a constant speed for 15min, adding yam powder into the stirring machine at intervals of 5min for 2 times, stirring at a constant speed for 15min, adding starch into the stirring machine at intervals of 5min for 2 times, stirring at a constant speed for 15min, adding schisandra chinensis powder into the stirring machine at intervals of 5min for 2 times, and stirring at a constant speed for 30 min. The processes are all finished in a 10 ten thousand grade purification environment;
(3) and (3) sterilization: uniformly spreading the material obtained in the step (2) on a stainless steel flat disc, dispersing the material to the thickness of about 1-2cm, carrying out dry heat sterilization at 80 +/-5 ℃ for 30min in a drying sterilization cabinet, taking out the material, and cooling the material to room temperature under the condition of 10 ten thousand-level purification;
(4) subpackaging: and (4) taking the material obtained in the step (3), subpackaging under the purification condition of 10 ten thousand grades, printing codes and labels, and packaging to obtain the product, wherein the specification is 15 g/bag.
Example 2
(1) Pretreatment of raw materials: weighing Shennong kudzu vine powder, baking in an oven at 50 +/-5 ℃ for 60min, sieving with a 60-mesh sieve, and collecting 200g of fine white powder below the sieve for later use; weighing corn starch, baking for 50min at 50 +/-5 ℃ in an oven, sieving with a 60-mesh sieve, and collecting 90g of undersize white fine powder for later use; weighing the Shennong Lianyao decoction pieces, baking in an oven at 60 +/-5 ℃ for 90min, crushing, sieving with a 60-mesh sieve, and collecting 55g of yellow fine powder below the sieve for later use; weighing Wudang yam, baking in an oven at 60 +/-5 ℃ for 90min, crushing, sieving with a 60-mesh sieve, and collecting 55g of undersize white fine powder for later use; weighing the Wudanghongling syringa mollis, baking the Wudanghongling syringa mollis in an oven at 50 +/-5 ℃ for 90min, crushing the Wudanghongling syringa mollis, sieving the Wudanghongling with a 60-mesh sieve, and collecting 100g of brownish black fine powder below the sieve for later use;
(2) mixing: sieving stevioside with a steel sieve with a diameter of 12cm and a 60-mesh sieve, mixing 0.2g stevioside and shennong kudzu vine powder, placing the mixed material in a stirring tank of a stirring machine, rotating the stirring machine to 60r/min at a high speed, stirring at a constant speed for 15min, adding bletilla striata powder into the stirring machine at intervals of 5min for 2 times, stirring at a constant speed for 15min, adding Chinese yam powder into the stirring machine at intervals of 5min for 2 times, stirring at a constant speed for 15min, adding starch into the stirring machine at intervals of 5min for 2 times, stirring at a constant speed for 15min, adding Chinese magnoliavine fruit powder into the stirring machine at intervals of 5min for 2 times, and stirring at a constant speed for 30 min. The processes are all finished in a 10 ten thousand grade purification environment; the semi-finished product to be subpackaged obtained in this step is shown in figure 2.
(3) And (3) sterilization: uniformly spreading the material obtained in the step (2) on a stainless steel flat disc, dispersing the material to the thickness of about 1-2cm, carrying out dry heat sterilization at 80 +/-5 ℃ for 30min in a drying sterilization cabinet, taking out the material, and cooling the material to room temperature under the condition of 10 ten thousand-level purification;
(4) subpackaging: and (4) taking the material obtained in the step (3), subpackaging under the purification condition of 10 ten thousand grades, printing codes and labels, and packaging to obtain the product, wherein the specification is 15 g/bag.
Example 3
(1) Pretreatment of raw materials: weighing Shennong kudzu vine powder, baking for 90min at 50 +/-5 ℃ in an oven, sieving with a 60-mesh sieve, and collecting 400g of fine white powder below the sieve for later use; weighing corn starch, baking in an oven at 50 +/-5 ℃ for 60min, sieving with a 60-mesh sieve, and collecting 180g of undersize white fine powder for later use; weighing the Shennong Lianyao decoction pieces, baking for 120min at 60 +/-5 ℃ in an oven, crushing, sieving by a 60-mesh sieve, and collecting 110g of yellow fine powder below the sieve for later use; weighing Wudang yam, baking in an oven at 60 +/-5 ℃ for 120min, crushing, sieving with a 60-mesh sieve, and collecting 110g of undersize white fine powder for later use; weighing the Wudanghongling Chinese magnoliavine fruit, baking for 120min at 50 +/-5 ℃ in an oven, crushing, sieving with a 60-mesh sieve, and collecting 200g of brownish black fine powder below the sieve for later use; the raw materials to be mixed in this example are shown in fig. 1, wherein the yellow fine powder is bletilla striata powder, the black fine powder is Wudanghong lingzi fine powder, and the white fine powder is Shennong kudzu vine powder.
(2) Mixing: sieving stevioside with a steel sieve with the aperture of 12cm and a mesh size of 60, mixing 0.4g stevioside and shennong kudzu vine powder, placing the mixed material in a stirring tank of a stirring machine, rotating the stirring machine to 60r/min at a high speed, stirring at a constant speed for 20min, adding bletilla striata powder into the stirring machine at intervals of 5min for 2 times, stirring at a constant speed for 20min, adding yam powder into the stirring machine at intervals of 5min for 2 times, stirring at a constant speed for 20min, adding starch into the stirring machine at intervals of 5min for 2 times, stirring at a constant speed for 20min, adding schisandra chinensis powder into the stirring machine at intervals of 5min for 2 times, and stirring at a constant speed for 25 min. The above processes are all completed in 10 ten thousand grade purification environment.
(3) And (3) sterilization: uniformly spreading the material obtained in the step (2) on a stainless steel flat disc, dispersing the material to the thickness of about 1-2cm, carrying out dry heat sterilization at 80 +/-5 ℃ for 30min in a drying sterilization cabinet, taking out the material, and cooling the material to room temperature under the condition of 10 ten thousand-level purification;
(4) subpackaging: and (4) taking the material obtained in the step (3), subpackaging under the purification condition of 10 ten thousand grades, printing codes and labels, and packaging to obtain the product, wherein the specification is 15 g/bag.
Comparative example 1
The difference from example 1 is that Wudangling Guiling was not added.
Comparative example 2
The difference is that the Shennong Liang Cao is not added as in example 1.
Comparative example 3
The difference is that the raw materials are directly mixed and added, and the mixture is stirred at a constant speed for 20min under the condition of 60r/min as in example 1.
Quality control
1.1 filling test (taking the food of example 1 as an example)
Taking 5 bags of the test article, removing labels, cleaning the outside of the bags by using a cotton swab, numbering, precisely weighing each bag, cutting the package along the upper edge of the bag opening, removing contents, cleaning the inner wall of each bag by using a proper method, precisely weighing each empty bag, and calculating the weight and the average weight of the contents in each bag. The average weight should be not less than the indicated weight and the weight per bag should be not less than 95% of the indicated weight.
1.2 qualitative identification
The three traditional Chinese medicines of the fructus syringae, the kudzu powder and the herba euphorbiae lathyris in the food all contain polysaccharide components, and the components can reduce the absorption of the stomach to alcohol and protect the gastric mucosa, so the polysaccharide is qualitatively identified by a nitration test:
① Positive control concentration is 1 mg/mL-12mL of bovine serum albumin reference solution is put into a test tube, 2 drops of concentrated nitric acid are dripped, the test tube is kept stand for 2 minutes, the color change is observed, and the result is yellow;
② putting 0.5g of the food in a test tube, adding 10mL of purified water, ultrasonically extracting for 20min, centrifuging, putting 2mL of supernatant in the test tube, dropwise adding 2 drops of concentrated nitric acid, standing for 2min, observing color change, and observing the color change to obtain yellow product with the same color as that of the control product;
③ negative control 2mL of purified water was put in a test tube, 2 drops of concentrated nitric acid were added dropwise, the tube was left to stand for 2 minutes, and color change was observed, resulting in clarification and no yellow color.
1.3 quantitative determination
The schizandrin A and the schizandrin B in the product of the invention play a main role in reducing transaminase, inhibiting alcoholic fatty liver and liver cirrhosis, and the schizandrin A content is higher than the schizandrin B, so that the detection is convenient, and the quantitative determination is carried out on the schizandrin A by taking the schizandrin A as an index.
1.3.1 measurement conditions
Model dell 3000 high performance liquid chromatography (dell, usa); FA2004 analytical balance (shanghai yi electronic analytical instrument factory, accuracy 0.00001 g); UP5200H ultrasonic oscillator (Nanjing panda electronic instruments factory, 600W, 40 HZ); a chromatographic column: Diamonsil-C18Columns (250 mm. times.4.6 mm,5 μm); mobile phase: methanol-water (65: 35); the detection wavelength is 250nm, the sample injection amount is 10 mu L, and the flow rate is 0.8 mL/min-1The column temperature was 25 ℃.
1.3.2 preparation of the solution
(1) Reference solutionLiquid: precisely weighing 10.0mg of deoxyschizandrin reference substance in a 100mL volumetric flask, adding methanol for dissolving, diluting to desired volume, shaking, sucking appropriate amount of the reference substance solution before use, filtering with 0.45um microporous membrane, and collecting filtrate to obtain 0.10 mg/mL-1And (4) a control solution.
(2) Test solution: precisely weighing 0.5g of the food in a 100mL volumetric flask, adding 50mL of methanol, performing ultrasonic extraction on an ultrasonic instrument for 20 minutes, taking out, placing to room temperature, adding methanol to a constant volume, filtering, volatilizing the filtrate in an evaporating dish, dissolving residues with a proper amount of methanol, transferring the solution to a 25mL volumetric flask, performing constant volume, shaking up, filtering with a 0.45 mu m microporous membrane, and taking a subsequent filtrate to obtain the food;
(3) blank solution: precisely weighing 0.5g of the product without the schisandra chinensis powder in a 100mL volumetric flask, and preparing according to a test solution method to obtain the schisandra chinensis powder.
1.3.3 device suitability test
Respectively sampling a reference solution, a test solution and a blank solution under the item of '1.3.2' under a '1.3.1' determination condition, recording a chromatogram, and obtaining a result: except the blank solution, the reference solution and the test solution have the same chromatographic peak at the same time, which indicates that the set determination conditions and other components in the food have no interference to the determination of the content of the deoxyschizandrin. The chromatogram is shown in FIG. 3.
1.3.4 measurement of content
Taking the foods of examples 1-3 and comparative examples 1-3, weighing 0.5g of the foods of examples 1-3 and comparative examples 3 bags in each batch, placing the weighed foods in a 100mL volumetric flask, preparing the foods according to the method of the test solution under the item of 1.3.2, carrying out sample injection under the measuring condition of 1.3.1 to measure the peak area, and calculating the content of deoxyschizandrin according to an external standard method, wherein the results are shown in Table 1.
TABLE 1 determination of deoxyschizandrin content in functional foods (n ═ 3)
1. Experiment on gastric mucosa protecting effect
1.1 Experimental animals
Taking 240 SD rats with the body weight of 200g (+ -20 g) and half of the body weight, dividing into 30 groups, wherein each group comprises 8 rats, namely a control group, a model group, a low-dose experiment group, a medium-dose experiment group and a high-dose experiment group; the big white rat is provided by an animal experiment center of Hubei medical institute, the license number of the experimental animal is SCXK (Hubei) 2016-; the experimental site is as follows: the Hubei institute of medicine attaches Taihe and Wudang institute of traditional Chinese medicine animal laboratory in hospital. Feeding conditions are as follows: the method is characterized by comprising the steps of keeping the temperature and humidity constant, feeding solid feed and sufficient vitamins every day, freely drinking water, feeding human care according to the 3R principle used by experimental animals, and feeding the animals for 1 week under the constant temperature condition before the experiment to keep good health.
1.2 instruments and reagents
RH2268 type electromagnetic oven (American electric company, power 1000W); TKY-TSI type tissue hydroextractor (Taikang medical devices Co., Ltd.); model KD-3368AM electronic tissue microtome (ketdi instruments equipment ltd); model BX43 electron microscope (olympus precision instruments); JC260ADL type biological tissue freezing and embedding machine (Nanjing Klodre mechanical Co., Ltd.); physiological saline (Sichuan Kelun pharmaceutical Co., Ltd., specification: 10mL, batch No. L118090806); a composition paste for nourishing stomach and protecting liver (prepared in examples 1-3 and comparative examples 1-3, 15g of the paste is taken, added with 200ml of water, mixed uniformly, placed in an electromagnetic oven, heated and boiled for about 3-5 minutes to form uniform paste, and prepared temporarily); absolute ethanol (Henan Sibo chemical products Co., Ltd., 20181113, content 99.99%);
1.3 Experimental methods
Respectively taking rats of each group, respectively performing intragastric administration for 1 time by using 1.2ml of physiological saline for a control group and a model group every day, respectively performing intragastric administration for 0.6g, 1.2g and 2.4g (calculated according to the weight of 6 mg/g) of the food for low, medium and high dose groups every day for 7 days by continuous intragastric administration, fasting without water prohibition before the 7 th intragastric administration after the 6 th intragastric administration, performing intragastric administration for 3 hours after the 7 th intragastric administration for the model group and the rats of the low, medium and high dose groups by using 1ml of absolute ethyl alcohol, killing the rats after 1 hour, taking out the whole stomach of the rat, soaking the whole stomach in 10% formalin solution for 1 hour, taking out the rat, shearing the rat along the greater curvature, purifying water to clean the stomach wall, and observing the injury condition of the stomach mucosa by naked eyes or under a microscope, wherein the condition is shown in figure 4. Rat stomach tissues were fixed with 10% formalin for 48 hours, then 4 μm was prepared, paraffin sections were cut, HE stained, and pathological morphological changes of the rat gastric mucosa of each group were observed under a microscope.
1.4 gastric tissue injury score criteria
① mucosal degeneration necrosis comprises 1 part without obvious pathological changes, 2 parts with local mild degeneration necrosis, 3 parts with most degeneration necrosis, 4 parts with whole mucosal degeneration necrosis, ② mucosal gland inflammatory cell infiltration degree, 1 part without inflammatory cell infiltration, 2 parts with few inflammation cell infiltration, 3 parts with most inflammation cell infiltration, 4 parts with most inflammation cell infiltration or abscess formation, ③ ulcer formation, 1 part without mucosal abscission, 2 parts with superficial mucosa abscission and mild erosion, 3 parts with severe erosion and 4 parts with whole mucosa abscission, ④ mucosal muscle inflammation reaction, 1 part without inflammatory cell infiltration, 2 parts with few inflammatory cells infiltration, 3 parts with more inflammatory cells infiltration, 4 parts with most inflammatory cells infiltration, fibroblast growth and granulation tissue formation, wherein the total score of the above 4 indexes is high, which indicates that the gastric mucosal tissue is damaged seriously, and the score is low, which indicates that the gastric mucosal tissue is damaged lightly.
1.5 statistical methods
Analyzing the grouping data and the treatment effect by SPSS17.0 software, and adopting Chi data as counting data2And (4) testing, wherein t test is adopted for measuring data, and P < 0.05 shows that the difference is obvious.
1.6 results
The histopathological scores of the rats in the low, medium and high dose groups are reduced in sequence, and the food has a dose-effect relationship on the protection of the gastric mucosa; the low-dose group has significant difference (P is less than 0.05) compared with the model group, and the medium-high dose group has very significant difference (P is less than 0.01) compared with the model group; the middle and high dose groups have no significant difference compared with the control group (P is more than 0.05). The results are shown in Table 2.
Note: a, comparing P with a model group to be less than 0.01; b comparison with model group P < 0.05
1.7 summary
The experimental results show that after 7 days of intragastric lavage protection, rats in all experimental groups (low dose group, medium dose group and high dose group) have different degrees of enhanced resistance to the injury of gastric mucosa induced by absolute ethyl alcohol; the food has different gastric perfusion amounts, and has different gastric tissue injuries of rats in low, medium and high dose groups, wherein the scores of the medium and high dose groups are closer to those of a control group, which indicates that the gastric mucosa of the rats in the medium and high dose groups is least damaged by absolute ethyl alcohol. The experimental result shows that the polysaccharide in the food has the effects of protecting and repairing the injured gastric mucosa of rats, reducing inflammatory factors, stopping bleeding and promoting wound healing. The food is also good in protection and repair effects on the human gastric mucosa injury caused by alcohol.
2 experiments on the anti-hangover Effect
2.1 Experimental animals
Taking 300 SD rats with the body weight of 200g (+ -20 g) and half each male and female, dividing into 30 groups, and respectively taking 10 rats in each group as a control group (normal saline), a model group, a low-dose experiment group, a medium-dose experiment group and a high-dose experiment group; the big white rat is provided by an animal experiment center of Hubei medical institute, the license number of the experimental animal is SCXK (Hubei) 2016-; the experimental site is as follows: the Hubei institute of medicine attaches Taihe and Wudang institute of traditional Chinese medicine animal laboratory in hospital. Feeding conditions are as follows: the method is characterized by comprising the steps of keeping the temperature and humidity constant, feeding solid feed and sufficient vitamins every day, freely drinking water, feeding human care according to the 3R principle used by experimental animals, and feeding the animals for 1 week under the constant temperature condition before the experiment to keep good health.
2.2 Experimental methods
The rats in each group were fasted for 12 hours before the experiment and weighed. The experimental group was first administered by gavage and then administeredThe food with medium and high dosage is prepared by mixing 15g of the product with 200ml of water, heating and boiling in an electromagnetic oven for 3-5 min to obtain a uniform paste, standing at room temperature, and preparing at a ratio of 1.0g/kg d-1Gavage), control group and model group were given physiological saline (at 1.0 g/kg. d)-1Gavage) for 7 days, and gavage with 50% ethanol at a dose of 0.4mL/10g for 30 minutes after the last 1-time gavage except for the control group to obtain drunk rats (preliminary experiments are carried out in advance, whether the righting reflex disappears is taken as a standard, the rats are placed in a mouse cage with their backs downward after gavage, and if the rats keep their postures with their backs downward for more than 30 seconds, the righting reflex disappears and the rats are judged to be drunk). Rats that died immediately after gavage and were not drunk for more than 3 hours were excluded.
2.3 blood alcohol detection
After 60 minutes of alcohol infusion, rats draw orbital venous blood, place the orbital venous blood in a heparin anticoagulation test tube for centrifugation to prepare serum, and store the serum at low temperature (2-8 ℃). Detecting ethanol concentration in rat serum by gas chromatography, and detecting equipment TRACETMModel 1319 gas chromatograph (Sailfeishel technologies, Ltd.) under chromatographic conditions of N2The flow rate is 2.0m L/min; the column temperature was initially 75 deg.C, increased to 120 deg.C at 8 deg.C/min, maintained for 2min, and then increased to 150 deg.C at 10 deg.C/min, maintained for 2 min. The headspace condition was 80 ℃ and the heating time was 300 s.
2.4 evaluation index
The hangover alleviating effect of the food is evaluated by taking the intoxication incubation period, the intoxication sleeping period and the blood alcohol concentration of the rats after being infused with 50 percent ethanol as indexes. The long latency period, the short drunk sleeping period and the low blood alcohol concentration indicate that the food has good effects of relieving ethanol poisoning, decomposing ethanol and metabolizing; the food has the advantages of short latency, long drunk sleep period and high blood alcohol concentration, and has relatively poor effects of relieving ethanol poisoning, decomposing ethanol and metabolizing.
2.5 statistical methods
Analyzing the grouping data and the treatment effect by SPSS17.0 software, and adopting Chi data as counting data2And (4) testing, wherein t test is adopted for measuring data, and P < 0.05 shows that the difference is obvious.
2.6 results
The incubation period is that the model group is smaller than the low dose group and smaller than the medium dose group and smaller than the high dose group, the low dose group has no significant difference (P is larger than 0.05) compared with the model group, and the medium and high dose groups have significant difference (P is smaller than 0.05) compared with the model group; in the drunk sleep period, the model group is larger than the low dose group, the medium dose group is larger than the high dose group, the low dose group has no significant difference (P is larger than 0.05) compared with the model group, and the medium and high dose groups have significant difference (P is smaller than 0.05) compared with the model group; the blood alcohol concentration, the model group > low dose > medium dose > high dose, the low dose group has no significant difference (P > 0.05) compared with the model group, and the medium and high dose groups have significant difference (P < 0.05) compared with the model group. See table 3.
Note: a, comparing P with a model group to be less than 0.05; b comparison with model groups P > 0.05
2.7 summary
The stomach filling amount is in direct proportion to the decomposed alcohol amount and correspondingly in inverse proportion to the blood alcohol concentration of the rats, and the result shows that the food has a good hangover alleviating effect. The experimental result also suggests that the absorption of alcohol in stomach and intestine can be delayed by people who eat the product before and after drinking and in the drinking process, which is beneficial to decomposing alcohol, preventing alcoholism and delaying and inhibiting drunkenness.
3 evaluation of Effect on suppressing alcoholic fatty liver
3.1 case data
700 patients with moderate alcoholic fatty liver signs and treated in digestive system department of the department of health in Taiwan and Hospital physical examination, who are detected in 2017, 1 month to 2018, 12 months in the department of health in the department of Taiwan, are screened, and are randomly divided into treatment groups (examples 1-3 and comparative examples 1-3) and control groups by a digital table method, wherein 100 patients are 100 in each treatment group, namely male 71 patients, female patients are 29 patients, the age is 30-60 years old, the average age is (42.60 +/-12.51), and the average course of disease is 12.80 +/-6.7 months; 68 men and 32 women in the control group, the age is 30-60 years, the mean age (43.20 +/-11.60) and the mean course is 13.10 (+ -8.4) months, and the sex, the age and the course of the two groups of patients have no significant difference (P > 0.05).
3.2 inclusion criteria
Refer to 'the consensus opinion of the non-alcoholic fatty liver disease and the Chinese and Western medicine combination diagnosis and treatment' revised by the Chinese society for the Integrated services of the digestive System diseases in 2011 ①, ② patients who have no endocrine, blood and digestive system diseases and have not taken related medicines 3 months before the experiment.
3.3 exclusion criteria
① severe dysfunction of heart, liver, stomach, and kidney;
② it is used for treating mental diseases, viral hepatitis, and liver cirrhosis.
3.4 methods of treatment
Advising all patients to abstain from alcohol, regularly work and rest, reasonably eat, properly exercise, add fruit, vegetable and protein food rich in vitamins and minerals, control fat intake, and avoid sweet food, hot and cold food. The control group orally takes the reduced glutathione tablet for 1 day and 3 times, and each time is 0.4 g; the treatment group takes 15g of the food (1 bag of the food is taken and added with about 200ml of water, mixed evenly and heated and boiled on an induction cooker for about 3-5 minutes to be pasty) on the basis of the control group in the morning and evening each day, 1 month is 1 treatment course, 1 treatment course is rechecked for 1 time after the 1 treatment course is finished, and 3 treatment courses are continuously treated.
3.5 evaluation index
Extracting about 3ml venous blood of each group of patients on an empty stomach before and after the treatment, performing anticoagulation treatment, centrifuging to prepare serum, detecting liver function index values of the two groups of patients before and after the treatment, including alanine Aminotransferase (ALT), aspartate Aminotransferase (AST) and alkaline phosphatase (ALP), and comparing the results; comparing the total effective rates of the two groups, and the judgment standard is as follows: and (3) curing: clinical symptoms disappear, and all indexes are recovered to be normal; the effect is shown: part of clinical symptoms disappear, and each detection index is reduced by more than or equal to 50 percent compared with that before treatment; improvement: part of clinical symptoms are relieved, and each detection index is reduced by more than or equal to 30 percent compared with that before treatment; and (4) invalidation: the clinical symptoms are not obviously improved, and each detection index is reduced by less than 30 percent compared with that before treatment. Total effective rate (number of cure cases + number of significant efficiency cases)/total number of cases × 100%.
3.6 statistical methods
Analyzing the grouping data and the treatment effect by SPSS17.0 software, and using Chi data as counting data2And (5) checking, namely checking the metering data by using t. P < 0.05 is significant difference.
3.7 results
3.7.1 liver function index
After 3 treatment courses, the ALT, AST and ALP 3 indexes of two groups of patients are obviously reduced (P is less than 0.05) compared with those before treatment in the group, and the 3 indexes in the treatment group are obviously different (P is less than 0.05) compared with those in the control group. The results are shown in Table 4.
Note: a is less than 0.05 in comparison with the control group
3.7.2 effective rate:
after two groups of patients are treated by 3 treatment courses, 63 patients are cured in 100 patients in the treatment group of example 1, the curative effect is 28 patients, 11 patients are improved, the curative effect is 3 patients, and the total effective rate is 91.0%; in the example 2, in 100 cases, 62 cases are cured, the obvious effect is 27 cases, 9 cases are improved, and 2 cases are invalid, and the total effective rate is 89.0%; example 3 in 100 cases, 60 cases are cured, the obvious effect is 30 cases, 8 cases are improved, and 2 cases are invalid, and the total effective rate is 90.0%; in a comparative example 1, 55 cases are cured in 100 cases, 21 cases have obvious effect, 19 cases are improved, 5 cases have no effect, and the total effective rate is 76.0 percent; in a comparative example 2 group, 61 cases are cured in 100 cases, 21 cases have obvious effect, 16 cases are improved, 2 cases have no effect, and the total effective rate is 82.0 percent; in a comparative example 3 group, 61 cases are cured in 100 cases, 27 cases are obviously effective, 9 cases are improved, 3 cases are ineffective, and the total effective rate is 88.0 percent; the control group has 100 cases for curing 44 cases, has obvious effect of 26 cases, improves 30 cases and has no effect of 4 cases, and the total effective rate is 70.0 percent. The treated group had significant differences (P < 0.05) compared to the control. See table 5.
TABLE 5 effective rate comparison (n,%) of alcoholic fatty liver of each group
Note: a is less than 0.05 in comparison with the control group
3.7.3 adverse reaction
During the treatment process, the mild rash appeared on the back of the hand of each of the patients in the treatment group and the patients in the control group, which may be caused by the oral administration of the reduced glutathione tablet, and the mild rash disappeared after the application of the budesonide ointment for 2 days. No other adverse reactions such as nausea, constipation, diarrhea and the like occur.
3.8 Small knot
Compared with the three indexes of ALT, AST and ALP after treatment, the treated group is superior to the control group, and has obvious difference (P is less than 0.05), which shows that the food has obvious improvement and promotion effect on the liver function of the alcoholic fatty liver as the dietary therapy auxiliary. The clinical application result shows that the effective rate of the treatment group to the alcoholic fatty liver is 21% higher than that of the control group, which shows that the food can obviously inhibit the damage of alcohol to liver cells, reduce transaminase, promote protein synthesis, stabilize liver cell membranes, improve liver cell structures, inhibit the formation of alcoholic fatty liver and liver cirrhosis, and has good protection effect on the liver.
3.9 examples of
3.9.1 Zhu XX, male, age 56, occupation, middle tube in bank, history of drinking over 20 years. The liver function of the patient is diagnosed as moderate alcoholic fatty liver in Tai Wei city and hospital examination center in 2017 and 4 months, no other diseases such as liver, kidney, heart, tumor and the like, ALT, AST and ALP are detected to be 95.65, 78.12 and 134.22 respectively before treatment, protein and vitamin foods are added according to the abstinence of wine, sweet food, hot and supercooled foods and reduced glutathione tablets are orally taken for 3 times in 1 day and 0.4 g/day, 15g of the food is taken in the morning and at the evening each day, 1 month is used for hospital reexamination for 1 time, and ALT, AST and ALP are respectively 37.84, 28.02 and 81.72 after 3 treatment courses, and the liver function is recovered to be normal. The self-describing lassitude and hypodynamia and inappetence disappear, and the clinical comprehensive evaluation is the cure treatment.
3.9.2 Chen X, male, 42 years old, occupation, staff of electric power company, drinking history more than 15 years, debilitation, lassitude and poor appetite from near 1 month, alcoholic fatty liver diagnosed in 5 months in 2018 in Tai Wei city and hospital physical examination center, except slight lumbar disc herniation, no other diseases such as liver, kidney, heart and tumor, ALT, AST and ALP detected before treatment are 101.12, 88.93 and 156.57 respectively, according to advice of abstinence, liver sweet food, high heat and supercooled food, vitamin and protein diet added, oral glutathione reduction tablet, 3 times in 1 day, 0.4 g/day, 15g of the food is taken in the morning and evening each day, 1 month is 1 course of treatment, 1 month is hospital recheck for 1 time and combined B ultrasonic examination, 3 courses of treatment are recheck ALT, AST and ALP are 40.64, 35.71 and 79.33 respectively, and recovery is normal. The self-describing diet returns to normal, the fatigue and the weakness disappear, and the clinical comprehensive evaluation is the cure.
3.9.3 Korean XX, female, age 45, occupation, officer, history of drinking over 15 years. The diagnosis of alcoholic fatty liver in 9 months in 2018 is made by physical examination in Tai Wei and Hospital examination center, which is classified as mild anorexia, and no other diseases such as liver, kidney, heart and tumor, and ALT, AST and ALP are detected as 97.78, 88.93 and 141.67 before treatment. According to the advice of a doctor, people abstain from alcohol, avoid sweet food, high-calorie and super-cold food, increase vitamins and high-protein diet, orally take reduced glutathione tablets for 3 times in 1 day, 0.4 g/day, take 15g of the food respectively in the morning and at night every day, 1 month is 1 course of treatment, 1 month is followed by hospital to review liver function plus B-ultrasound, and after 3 courses of treatment, the ALT, AST and ALP are respectively 33.25, 36.17 and 80.53, and the normal state is recovered. The diet returns to normal without fatigue and fatigue, and the clinical comprehensive evaluation is a cure.
With the rapid development of market economy and the improvement of living standard of substances, drinking is an important content indispensable to social activities, the damage to the stomach and the liver caused by the increase of drinking and the excessive drinking is obvious, and the health problems caused by the damage are increased by gastric mucosal ulcer, gastric bleeding and alcoholic liver, especially by male. Besides changing dietary habits, reducing drinking, moderate drinking and reducing the damage of drunkenness to the stomach and the liver, the taking of functional food with the functions of nourishing the stomach, protecting the liver and relieving alcoholism after meals is an important method for guaranteeing body health and renovating the dietary habits. Therefore, the research and development of functional food with the functions of protecting liver, nourishing stomach and relieving alcoholism has important significance for guaranteeing the health of people, the functional food is different from pure medicines, has double functions of health care and treatment, does not have the side effect of medicines, does not generate a sequela effect, can be eaten as food and beverage all the year round, and plays the functions of nourishing stomach, protecting liver and relieving alcoholism after drinking before and after meals. The functional food provided by the invention has the advantages that the main raw materials are natural Chinese herbal medicines, the auxiliary materials are food materials, the formula is novel, the process is scientific, the quality is stable and controllable, the daily health care requirements are met, animal experiments and clinical verification prove that the food is safe, effective, practical, convenient and economical, is suitable for families and hotels, is also suitable for online and offline sales, and has wide market prospects.
The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.
Claims (10)
1. The composition for nourishing the stomach, protecting the liver and relieving alcoholism is characterized by comprising the following raw materials: the weight ratio of the schisandra fruit, the arrowroot, the bletilla striata, the yam, the starch and the stevioside is (1-3): 2-5): 0.9-1.2): 1.5-2.0): 0.002-0.005.
2. The composition for nourishing stomach, protecting liver and alleviating hangover as claimed in claim 1, wherein the weight ratio of the schisandra chinensis, the arrowroot, the bletilla striata, the yam, the starch and the stevioside is 2:4:1.1:1.1:1.8:0.004 in sequence.
3. The preparation method of the composition for nourishing stomach, protecting liver and alleviating hangover according to claim 1, comprising the following steps:
(1) preprocessing schisandra chinensis, arrowroot, rhizoma bletillae, yam and starch in the raw materials to obtain corresponding powder;
(2) sieving stevioside, mixing stevioside and radix Puerariae powder, placing in a stirrer, and stirring;
(3) adding rhizoma bletilla powder into the stirrer for 2 times, and stirring;
(4) adding the yam powder into a stirrer for 2 times, and stirring;
(5) adding starch into a stirrer for 2 times, and stirring;
(6) adding fructus Schisandrae chinensis powder into a stirrer for 2 times, and stirring;
(7) uniformly spreading the material obtained in the step (6) on a stainless steel flat plate, sterilizing and cooling to room temperature;
(8) subpackaging, printing code and labeling, and packaging.
4. The preparation method of the composition for nourishing the stomach, protecting the liver and alleviating hangover as claimed in claim 3, wherein the processes of step (1) to step (8) are performed in a 10 ten thousand-level clean environment.
5. The preparation method of the composition for nourishing the stomach, protecting the liver and alleviating hangover as claimed in claim 3, wherein the pretreatment in the step (1) is baking in an oven, sieving, and collecting powder.
6. The preparation method of the composition for nourishing stomach, protecting liver and alleviating hangover as claimed in claim 3, wherein the stevioside of step (2) is sieved by a steel sieve with an aperture of 12cm and a 60-mesh sieve, and then mixed with the arrowroot, and the rotation speed of the stirrer is 50-70r/min, and the stirring is carried out at a constant speed for 10-20 min.
7. The preparation method of the composition for nourishing stomach, protecting liver and alleviating hangover as claimed in claim 3, wherein the rhizoma bletillae powder of step (3) is added at 2 intervals of 5-8min, the rotation speed of the stirrer is 50-70r/min, and the stirring is performed at a constant speed for 10-20 min.
8. The preparation method of the composition for nourishing stomach, protecting liver and alleviating hangover as claimed in claim 1, wherein the yam of step (4) and the starch of step (5) are added at 2 intervals of 5-8min, respectively, and the rotation speed of the stirrer is 50-70r/min, and the uniform stirring is performed for 10-20 min.
9. The preparation method of the composition for nourishing stomach, protecting liver and alleviating hangover as claimed in claim 1, wherein the fructus Schisandrae chinensis powder in step (6) is added at 2 intervals of 5-8min, the rotation speed of the stirrer is 50-70r/min, and the stirring is performed at constant speed for 25-35 min.
10. The method for preparing the composition for nourishing stomach, protecting liver and alleviating hangover as claimed in claim 1, wherein the dispersion thickness in the step (7) is 1-2cm, and the sterilization is performed at 70-90 ℃ for 20-30 min.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010237660.7A CN111281939A (en) | 2020-03-30 | 2020-03-30 | Composition for nourishing stomach, protecting liver and dispelling effects of alcohol and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010237660.7A CN111281939A (en) | 2020-03-30 | 2020-03-30 | Composition for nourishing stomach, protecting liver and dispelling effects of alcohol and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111281939A true CN111281939A (en) | 2020-06-16 |
Family
ID=71022106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010237660.7A Pending CN111281939A (en) | 2020-03-30 | 2020-03-30 | Composition for nourishing stomach, protecting liver and dispelling effects of alcohol and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111281939A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1058907A (en) * | 1990-08-15 | 1992-02-26 | 于宗亮 | The prescription of Antialcoholic liver-protecting oral liquid and manufacturing process |
CN103432248A (en) * | 2013-08-21 | 2013-12-11 | 雷雨田 | Health-care product for protecting liver from alcohol damage and nourishing stomach and preparation method thereof |
-
2020
- 2020-03-30 CN CN202010237660.7A patent/CN111281939A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1058907A (en) * | 1990-08-15 | 1992-02-26 | 于宗亮 | The prescription of Antialcoholic liver-protecting oral liquid and manufacturing process |
CN103432248A (en) * | 2013-08-21 | 2013-12-11 | 雷雨田 | Health-care product for protecting liver from alcohol damage and nourishing stomach and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
顾维雄: "《怎样选择保健食品》", 31 August 2002, 上海人民出版社 * |
高学敏: "《中药学》", 30 June 2017, 中国协和医科大学出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106975012B (en) | Traditional Chinese medicine composition for reducing blood sugar and preparation method thereof | |
CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
CN100418562C (en) | Medicinal composition, its preparing method and quality controlling means | |
CN102551046A (en) | Natural health composition for weight reduction and application of same | |
CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
CN107136245A (en) | A kind of pure draft fat-reducing tea bag health food and preparation method thereof | |
CN111317775A (en) | Application of preparation for removing food retention and relieving cough for children in preparation of medicine for treating fever and preparation method thereof | |
CN111298021A (en) | Traditional Chinese medicine composition for treating functional constipation | |
CN107496725B (en) | Composition containing Malus hupehensis and bamboo extract as effective components and application thereof | |
CN106310017B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung and kidney qi deficiency syndrome | |
CN111281939A (en) | Composition for nourishing stomach, protecting liver and dispelling effects of alcohol and preparation method thereof | |
WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
CN102309705A (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
CN101693086B (en) | Traditional Chinese medicine compound preparation for preventing recurrent aphthae, preparation method and application thereof | |
CN101816708B (en) | Chinese medicinal composition for curing rheumatism and preparation method thereof | |
CN110720527A (en) | Traditional Chinese medicine weight-losing tea | |
CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
JP2000236835A (en) | Food prepared by using koto-sugi as main raw material and its preparation | |
CN100358553C (en) | Chinese medicine composition for lowering blood fat and reducing weight and preparation thereof | |
CN112494626B (en) | Tablet with protective effect on chemical liver injury and preparation method thereof | |
CN112544973B (en) | Auxiliary blood lipid-lowering composition, compound granule prepared from same, and preparation method and application of compound granule | |
CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
CN112336830B (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |